Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/3/2021 | $3.50 → $2.50 | Buy | HC Wainwright & Co. |
| 9/13/2021 | $7.00 → $3.50 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $6.00 → $5.00 | Outperform | RBC Capital |
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $2.50 from $3.50 previously
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $3.50 from $7.00 previously
RBC Capital reiterated coverage of Agile Therapeutics with a rating of Outperform and set a new price target of $5.00 from $6.00 previously
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
Appointment of Experienced HR Executive Suzanne Hinchcliffe to Chief People Officer Continues Buildout of Experienced Leadership Team GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer. This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer a
Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. Appointment of Ernie De Paloantonio to
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,